# A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

> **NCT00798265** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 26 (actual)

## Conditions studied

- Human Immunodeficiency Virus
- Human Papillomavirus- 6, 11, 16, 18
- Adolescent
- Papillomavirus Vaccines

## Interventions

- **BIOLOGICAL:** Gardasil
- **BEHAVIORAL:** Survey

## Key facts

- **NCT ID:** NCT00798265
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06-29
- **Primary completion:** 2012-09-22
- **Final completion:** 2013-02-04
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Study closed due to low accrual.
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00798265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00798265, "A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00798265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*